Why the study?
Does AT2R deficiency or blockade delay tumorigenesis and inhibit tumor angiogenesis in mouse models?
Population
Two animal tumor models: fibrosarcoma induced by 3-methylcholanthrene in FVB/N mice and carcinoma LL/2 cells…
Comparison
Angiotensin II Type 2 receptor invalidation or… vs Wild-type mice or untreated mice
Design
Preclinical
Follow-up
Up to 56 days
Authors
Loading...
AT2R blockade may merit exploration as a cancer target; leaves open translation from mouse models to human therapy.
Does AT2R deficiency or blockade delay tumorigenesis and inhibit tumor angiogenesis in mouse models?
Deficiency or blockade of the angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis in mouse models.
Clere et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: